Pathological complete response in younger and older breast cancer patients
- PMID: 22662005
- PMCID: PMC3361044
- DOI: 10.5114/aoms.2012.28559
Pathological complete response in younger and older breast cancer patients
Abstract
Introduction: Pathologic complete response (pCR) after neoadjuvant systemic treatment for inoperable locally advanced breast cancer is defined as complete microscopic disappearance of invasive cancer in both the breast and axilla in the postoperative specimen. The aim of the study was to characterize the groups of younger (≤ 40 years old) and older (≥ 70 years old) breast cancer patients who achieved a pCR.
Material and methods: One hundred thirty-eight consecutive patients aged between 30 and 78 years with locally advanced breast cancer, operated on after neoadjuvant systemic treatment between November 2007 and June 2010, were analyzed. In this group 9 women (6.5%) were 40 years of age or younger, and 12 patients (8.7%) were 70 years of age or older.
Results: In the younger group, pCR was achieved in 1 patient with triple negative, invasive ductal breast cancer, G3, BRCA 1 mutation, treated with cisplatin. A near pCR was achieved in 2 other patients, with triple negative, invasive ductal breast cancer, G3, treated with AT. The pCR in the breast was found in a HER2 positive patient. In older patients, pCR was achieved in 2 patients with triple negative, invasive ductal breast cancer, G3, treated with AT or FEC. Pathologic complete response in the axilla was achieved in 1 patient with triple negative, ductal carcinoma. The pCR rates were significantly higher in triple negative breast cancer in both groups (p = 0.047 and p = 0.018, respectively).
Conclusions: Pathologic complete response was significantly associated with receptor- based subtypes in both young and old women.
Keywords: breast cancer; elderly; pathological complete response; young.
Similar articles
-
Predicting breast and axillary response after neoadjuvant treatment for breast cancer: The role of histology vs receptor status.Breast J. 2018 Nov;24(6):894-901. doi: 10.1111/tbj.13085. Epub 2018 Jul 22. Breast J. 2018. PMID: 30033607
-
Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.Cancer. 2013 May 15;119(10):1776-83. doi: 10.1002/cncr.27995. Epub 2013 Feb 21. Cancer. 2013. PMID: 23436342 Free PMC article.
-
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.J Clin Oncol. 2012 May 20;30(15):1796-804. doi: 10.1200/JCO.2011.38.8595. Epub 2012 Apr 16. J Clin Oncol. 2012. PMID: 22508812
-
[Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].Zhonghua Zhong Liu Za Zhi. 2012 Oct;34(10):770-4. doi: 10.3760/cma.j.issn.0253-3766.2012.10.011. Zhonghua Zhong Liu Za Zhi. 2012. PMID: 23291072 Clinical Trial. Chinese.
-
Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy.Biomed J. 2019 Feb;42(1):66-74. doi: 10.1016/j.bj.2018.10.007. Epub 2019 Mar 28. Biomed J. 2019. PMID: 30987708 Free PMC article.
Cited by
-
Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in invasive breast cancer in women.Arch Med Sci. 2013 Jun 20;9(3):466-71. doi: 10.5114/aoms.2012.31010. Epub 2012 Oct 16. Arch Med Sci. 2013. PMID: 23847668 Free PMC article.
-
Cytotoxic and targeted therapy for hereditary cancers.Hered Cancer Clin Pract. 2016 Aug 23;14(1):17. doi: 10.1186/s13053-016-0057-2. eCollection 2016. Hered Cancer Clin Pract. 2016. PMID: 27555886 Free PMC article. Review.
-
The influence of steroid receptor status on the cardiotoxicity risk in HER2-positive breast cancer patients receiving trastuzumab.Arch Med Sci. 2015 Apr 25;11(2):371-7. doi: 10.5114/aoms.2015.50969. Epub 2015 Apr 23. Arch Med Sci. 2015. PMID: 25995754 Free PMC article.
-
Immunohistochemical evaluation of osteopontin expression in triple-negative breast cancer.Arch Med Sci. 2020 Apr 5;20(2):436-443. doi: 10.5114/aoms.2020.93695. eCollection 2024. Arch Med Sci. 2020. PMID: 38757015 Free PMC article.
-
Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis.Hered Cancer Clin Pract. 2022 Sep 9;20(1):34. doi: 10.1186/s13053-022-00242-0. Hered Cancer Clin Pract. 2022. PMID: 36085046 Free PMC article. Review.
References
-
- Bhargava R, Beriwal S, Dabbs DJ, et al. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy. Cancer. 2010;116:1431–9. - PubMed
-
- Bernsdorf M, Ingvar C, Jorgensen L, et al. Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in randomized phase II trial. Breast Cancer Res Treat. 2011 Jan 15; [Epub ahead of print] - PubMed
-
- Tubiana-Hulin M, Stevens D, Lasry S, et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Onc. 2006;17:1228–33. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous